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Cardiovascular Disease among Syrian
refugees: a descriptive study of patients in
two Médecins Sans Frontières clinics in
northern Lebanon
Philippa Boulle1†, Albane Sibourd-Baudry1†, Éimhín Ansbro2* , David Prieto Merino2, Nadine Saleh3,
Rouba Karen Zeidan4 and Pablo Perel2
Abstract
Background: Literature on the burden and management of atherosclerotic cardiovascular disease (ASCVD) in
humanitarian settings is limited. This study aimed to describe patient characteristics and explore both service use
and use of recommended secondary prevention drugs in Syrian refugee patients with ASCVD attending two
Médecins Sans Frontières (MSF) clinics in Lebanon.
Methods: This study comprised a cross-sectional survey of ASCVD patients attending either MSF clinic over a four-
week period in early 2017. Using descriptive statistics, we explored patient demographic characteristics,
cardiovascular risk factors and assessed ASCVD secondary prevention medication prescription and patient
adherence with a 7-day self-report scale. A retrospective study of routine clinical data explored workload and trends
in patient loss to follow-up. We performed logistic regression modelling to explore risk factors for loss to follow-up.
Results: We included 514 patients with ASCVD in the cross-sectional study, performed in 2017. Most (61.9%) were
male and mean age was 60.4 years (95% CI, 59.6–61.3). Over half (58.8%) underwent revascularization and 26.1%
had known cerebrovascular disease. ASCVD risk factors included 51.8% with diabetes and 72.2% with hypertension.
While prescription (75.7 to 98.2%) and self-reported adherence rates (78.4 to 93.9%) for individual ASCVD secondary
prevention drugs (ACE-inhibitor, statin and antiplatelet) were high, the use of all three was low at 41.3% (CI95%:
37.0–45.6). The 5-year retrospective cohort study (ending April 2017) identified 1286 patients with ASCVD and 16,
618 related consultations (comprising 24% of all NCD consultations). Over one third (39.7%) of patients were lost to
follow-up, with lower risk among men.
Conclusions: The burden of ASCVD within MSF clinics in Lebanon is substantial. Although prescription and
adherence of individual secondary prevention drugs is acceptable, overall use of the three recommended drugs is
suboptimal. Loss to follow-up rates were high. Further studies are needed to evaluate innovative strategies to
increase the use of the multiple recommended drugs, and to increase the retention of patients with ASCVD in the
care system.
Keywords: Cardiovascular disease, ASCVD, Refugee, Syria, Lebanon, Adherence, Humanitarian assistance, Secondary
prevention
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Background
Non-communicable diseases (NCD) have become a
major public health issue worldwide. Cardiovascular dis-
eases (CVDs), cancer, diabetes and chronic lung diseases
are the four key NCDs highlighted by WHO [1, 2]. Their
burden continues to grow globally, but at a higher rate
in low- and middle-income countries (LMICs). Among
the 70% (40 million) of global deaths due to NCDs in
2016, CVDs were the leading cause (17.7 million) [2]. In
addition, there are an estimated 422.7 million prevalent
cases of CVD [1, 3]. Over three quarters of global CVD
deaths occur in LMICs, which also bear the burden of
most premature deaths (under the age of 70) [4].
Atherosclerotic cardiovascular diseases (ASCVDs),
including coronary heart disease, stroke and peripheral
vascular diseases, are the most common types of CVD,
and patients with existing ASCVD are a population at
particularly high risk of suffering a new CVD event [5].
Fortunately, there is high-quality evidence supporting
the cost-effectiveness of pharmacological treatment for
the secondary prevention of CVD events in patients with
ASCVD, including β-blockers, angiotensin-converting-
enzyme inhibitors (ACE-Is), statins, and aspirin. These
interventions are recommended by all major inter-
national guidelines [6–8]. However, the use of this
pharmacological treatment is worryingly low worldwide
and remains a critical issue in LMICs where up to 80%
of ASCVD patients do not have access to even one of
the recommended drugs [9, 10].
As the global burden increases, medical humanitarian
organisations, such as Médecins sans Frontières (MSF),
are increasingly faced with patients needing care for
NCDs, including those with ASCVD. While there is
growing evidence on the burden and gaps in access to
care for NCDs in humanitarian crisis settings, very little
has been published on the cost effective management of
NCDs in general, and still less on the management of
ASCVD, in humanitarian settings [11–15]. This is a sig-
nificant gap, especially given that limited evidence shows
that crises may actually increase CVD mortality, morbid-
ity and risk factors [12, 16–18]. Commentators have
noted the challenges that exist around identifying and
treating ASCVD even in high-income, stable settings
with ready access to medications and diagnostics [19].
It may be more challenging still in crises, given the
potential health system disruption, the lack of pre-crisis
capacity or access to ASCVD medical management,
diagnostics and interventions in many LMICs (particu-
larly at primary care level), and humanitarian actors’
relative inexperience in managing ASCVD. The MSF
approach in many settings has been to provide a regular
supply of good quality, secondary prevention medica-
tions at primary care level along with adherence support
for patients with a self-reported history of ASCVD but,
thus far, ASCVD cohorts have not been characterised
and this approach has not been evaluated.
Over six million Syrians have left their country since the
start of the Syrian conflict in 2011 [20]. Neighbouring
Lebanon has a national population of around 4 million,
and currently hosts an estimated 1.5 million Syrian refu-
gees, of whom just over 1 million are registered with the
United Nations High Commissioner for Refugees
(UNHCR) [21–23]. NCDs are highly prevalent among the
Syrian population. Prior to the conflict, 77% of all deaths in
Syria were caused by NCDs, with CVD alone responsible
for 44% [24]. A 2014 survey of Syrian refugees in Lebanon
found that 50.4% of surveyed households reported at least
one member with a chronic condition, including cardiovas-
cular disease in 10.8% of the households [25].
The Lebanese Ministry of Public Health (MoPH) and
UNHCR coordinate a complex group of providers to serve
Syrian refugees, and UNHCR-registered refugees can ac-
cess a network of primary care centres [15]. However, they
are required to make subsidised co-payments for consulta-
tions, medications and referrals for hospital treatment;
accessibility varies between areas; and access to hos-
pital-based services is very limited [15, 26].
Registration of Syrian refugees by UNHCR was
suspended in May 2015, following Lebanese govern-
ment instruction, and unregistered refugees are lim-
ited to attending facilities funded by private donors
or humanitarian organisations, such as MSF [15, 27].
MSF has been providing free-of-charge healthcare to
Syrian refugees and the vulnerable host community in
Lebanon, in parallel to the MOPH system, since early
2012 in both northern Lebanon and in the Bekaa valley.
At the time of the study, MSF was providing integrated
primary health care (PHC) with general PHC consulta-
tions, sexual and reproductive health, mental health and
NCD outpatient care, including secondary prevention
for patients with ASCVD.
This study aimed to describe the magnitude of the
burden of ASCVD in patients seeking care in two MSF
clinics in northern Lebanon, and the characteristics and
pattern of care of these patients.
Specifically, our objectives were to describe patients
with ASCVD in terms of:
1) Frequency of the different atherosclerotic
cardiovascular conditions
2) Demographic characteristics
3) Medication prescription, adherence and use
4) Pattern of follow-up
Our final goal was to identify current challenges in the
model of care in order to find ways to improve the
management of patients with ASCVD in the humanitarian
context.
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Method
Study design
This is a descriptive study with two components: a
cross-sectional survey and a retrospective cohort study.
Setting
The study took place in two MSF clinics in northern
Lebanon. Dar Al Zahara (DAZ) clinic, open since 2012, is
located within a hospital in Tripoli town, North Lebanon
governorate. Abdeh clinic, open since April 2015, is situ-
ated in Abdeh village, in Akkar governorate north of
Tripoli. In both, MSF is providing integrated primary
health care to Syrian refugees and vulnerable Lebanese, in-
cluding NCD care for the following chronic conditions:
hypertension, diabetes, cardiovascular disease, epilepsy,
hypothyroidism and chronic respiratory disorders. At the
time of the study NCD care was offered only to non-Leba-
nese nationals as Lebanese patients could access such care
through a national NCD program.
For ASCVD patients (as for other NCD patients), the of-
fered services included consultations, the provision of es-
sential medications, access to basic investigations, patient
education and when necessary, specialist referral. There
was an appointment system for patient consultations, but
no system to remind patients of upcoming appointments.
Care was provided by non-specialist general practitioners
(GPs) and nurses, supported by an international specialist
doctor. Nurses saw all patients for a check of vital signs,
and to organise medication refill if patients fit specific cri-
teria of stability. Patients were then referred to the doctor
in case of complications or for every third visit. Laboratory
tests were performed on site through point-of-care tests in
Abdeh clinic, and in the hospital laboratory in DAZ clinic,
according to a rationalised schedule of routine investiga-
tions. Patient education, including on hypertension and
ASCVD, was provided in the waiting areas by health pro-
motion staff, and individually to patients by trained nurses.
Medications and related instructions were given by a phar-
macy dispenser nurse. All information collected during
consultations was recorded on individual paper files kept
at the clinic, and then routinely entered into an MSF data-
base in a disaggregated manner.
Consultation frequency was usually monthly, with
consultations of two-monthly frequency being imple-
mented once patients had reached target blood pres-
sure. Patients were treated according to MSF
protocols, which were adapted for the local context
from leading international guidelines. For the second-
ary prevention of ASCVD, they involved the concomi-
tant use of an antiplatelet agent and statin, and
potentially ACE inhibitors and β-blockers. Relevant
extracts from MSF’s Integrated Clinical Pathway for
Patients at High Cardiovascular Risk are available in a
supplementary file [see Additional file 1].
Participants, data sources and collection
Cross-sectional survey
The cross-sectional survey aimed to describe the charac-
teristics of ASCVD patients.
Participants: The study inclusion criteria were patients
aged 18 years and older with established atherosclerotic
cardiovascular disease [history of coronary heart disease
(CHD), cerebrovascular disease, or peripheral vascular
disease (PVD)] enrolled in the NCD cohort of DAZ and
Abdeh MSF clinics in northern Lebanon, attending the
clinic during a four-week period between March 8th and
April 5th 2017.
Variables collected:
1) Demographic and socio-economic characteristics
(age, gender, country of origin, refugee status,
address, occupation) as well as date of enrolment in
MSF NCD cohort,
2) ASCVD diagnoses,
3) Cardiovascular risk factors,
4) Cardiovascular secondary prevention medications
prescribed (including date of initiation and current
daily dose),
5) Self-reported adherence, and
6) Causes of non-adherence.
ASCVD diagnoses were grouped as (a) Coronary heart
disease [myocardial infarction (MI) and angina], (b)
cerebrovascular disease [stroke, transient ischaemic
attack (TIA)], (c) PVD, (d) previous revascularization
[percutaneous coronary angioplasty (PTCA) and coron-
ary artery bypass graft (CABG)]. These were largely
based on self-report, although a limited number of refu-
gees arrived in Lebanon with medical records confirming
their prior ASCVD diagnoses and patients diagnosed
since arrival in Lebanon usually had their diagnoses
medically confirmed.
Cardiovascular risk factors collected were: comorbid
diabetes, hypertension and current smoking. These were
primarily based on self-report, unless the diabetes or
hypertension had been newly diagnosed by MSF staff.
Self-reported adherence was assessed using a purpose-
designed tool, asking patients the number of days they
had taken the relevant drugs as prescribed (the correct
number of pills per day) during the previous 7 days, as
has been done in other studies [28]. This question was
asked for each class of drug they were prescribed for
secondary prevention of ASCVD (ACE-I, statin, β-
blocker, antiplatelet agent). The patient was considered
adherent, for each drug, if the correct number of pills
was taken for 5 days or more.
The reasons for non-adherence to any of the recom-
mended drugs were systematically explored using a pre-
defined checklist and were based on self-report. The
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checklist was adapted following a total of eighteen pre-
tests, which were performed in both clinics. The patient
was asked to volunteer a reason for non-adherence and
the nurse then applied a checklist category or detailed it
under “other”. The categories were: on doctor’s instruc-
tions, forgetfulness, unable to attend clinic, feeling
unwell, side effects due to the drug, choosing to take the
drug not as prescribed, taking too many drugs, indiffer-
ence, don’t know (e.g. family member handling drugs),
other. An additional reason, “did not understand pre-
scription”, was added after the study commenced since
staff frequently encountered this response. We also
explored frequency of drug “use”, aiming to capture both
adherence by clinicians to prescribing guidelines (via
clinical records) and adherence by the patient to taking
medications as prescribed (via self-report).
Data sources and collection:
A case report form (CRF) was designed to collect the
required information. Every eligible patient seeking care
at one of the two MSF clinics during the study period
was invited to participate in the study, and every
consenting patient signed an informed consent form.
The 4-week period was chosen to maximise participa-
tion as the majority of the ASCVD patients were still on
a monthly follow-up routine. We expected that approxi-
mately 500 patients would fulfil the eligibility criteria.
With this sample size, the expected precision for adher-
ence lay between 4.29 and 3.13% for a true prevalence
between 60 and 85%.
Each clinic had its own team in charge of implement-
ing the CRF. The NCD nurse was in charge of identify-
ing eligible patients and obtaining informed consent. For
consenting patients, the GP filled the ASCVD history
and prescription parts of the CRF and referred the pa-
tient to the Patient Support Education and Counselling
(PSEC) nurse after the consultation. The PSEC nurse re-
corded the demographic and adherence information on
the CRF.
All clinical MSF staff involved in the cross-sectional
part of the study were trained on their specific roles and
the process for filling the CRF was the same in the two
clinics. A pilot test was performed on 8 to 10 patients in
each clinic and the CRF was adapted according to the
feedback received.
Retrospective cohort study
The objective of the retrospective cohort study was to
analyse the burden of ASCVD in patients attending for
medical care at MSF clinics in northern Lebanon, as well
as the pattern of follow up visits.
Participants
The study inclusion criteria were patients aged 18 years
and older with established atherosclerotic cardiovascular
disease (history of CHD, cerebrovascular disease, or
PVD) enrolled in the NCD cohort of DAZ and Abdeh
MSF clinics in northern Lebanon and attending either
clinic since its opening until the end of April 2017.
Data, sources, and collection
Data regarding visit dates, type (planned/unplanned) and
frequency for all ASCVD patients since the opening of
each clinic were extracted from the MSF NCD database
containing routinely collected data. These data were
cleaned before analysis.
Statistical analysis methods
Categorical variables were described with proportions
and continuous variables were summarized with means
overall and per clinic. We calculated confidence intervals
for the overall estimates and for the clinic level means
and proportions.
We explored whether some baseline demographics
(sex, age, resident permit, Arabic literacy), time from
first visit and clinical factors (ASCVD diagnosis, risk
factors) were associated with non-adherence. We coded
the factors into binary variables and we used Fisher’s
exact tests to compare the proportion of adherent
patients between the two categories of each variable.
Patients who were prescribed an ACE-I, statin, β-
blocker or antiplatelet agent for the first time at the sur-
vey visit were not included in this analysis (unless they
were new patients). This was due to a concern that the
prescription of such drugs to existing patients at that
visit may have been a “corrective measure” taken by the
GPs who were responsible for filling out the section of
the CRF on prescribed medicines. Additionally, self-re-
ported adherence for angiotensin II receptor blockers
(ARBs) was not asked. For the self-adherence analysis,
we assumed that adherence to ARBs would have been
the same as that for ACE-Is.
With the dates of visits from the retrospective cohort
we calculated the number of visits and estimated
distribution of delay between visits. We defined a “loss to
follow up” (LTFU) episode when a patient had no contact
with the clinic for 100 or more consecutive days. We cal-
culated the distribution of LTFU episodes in the patients
and we used a logistic regression model to analyse
whether sex and age at baseline, only, were associated with
the risk of having at least one loss to follow up episode.
The model was adjusted for time since enrolment.
Ethical approval
This study received ethical approval from the MSF ethics
review board and from the Lebanese University ethical
review board.
Our findings are reported here according to STROBE
statement guidelines for observational studies [29].
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Results
Cross-sectional study
A total of 545 eligible patients with ASCVD were identified
during the 4-week period, of whom 94.3% (514) accepted
to participate (238 in Abdeh clinic and 276 in DAZ clinic).
31 patients refused to participate, of whom 77% were in
Abdeh clinic (n = 24). A third did not give any reason for
their decision, 23% had no time to spare, 16% did not feel
comfortable participating in a study and a quarter said they
did not need/want any improvement in the care they re-
ceived in MSF clinics (the study was presented as a step for
MSF to improve the quality of care being provided).
Patient characteristics
Of the 514 patients who participated, 98.8% of them
were Syrian refugees, among whom 98.2% were regis-
tered with UNHCR. Table 1 shows the main characteris-
tics of the patients.
Demographic characteristics of the ASCVD patients
were comparable between the 2 clinics: mean age of 60.4
(95% CI: 59.6–61.3) years old, majority male (61.9%) and
over half literate in Arabic (58.9%). The proportion of
patients with a valid resident permit was significantly
higher in DAZ than in Abdeh, but still low in both loca-
tions, at 33.3 and 20.2% respectively.
With respect to ASCVD history, more than half of the
patients (58.5%) had at least one revascularisation (CABG
or PTCA), with a higher proportion in Abdeh (66%) com-
pared to DAZ (52.5%). The reported prevalence of CHD
was very different between the 2 clinics with only 13% in
Abdeh but 47.5% in DAZ. A quarter (26.1%) had a diagno-
sis of cerebrovascular disease, while only 1.8% had been
diagnosed with PVD. About 1 in 5 of the recruited pa-
tients (18%) had more than one ASCVD diagnosis.
Regarding cardiovascular risk factors, about half of the
patients (51.6%) had diabetes. A majority had hyperten-
sion (72.2%); the proportion was higher in DAZ (77.2%)
than in Abdeh (66%). Almost 40% of the patients were
current smokers. About 1 in 10 of the recruited patients
(12.1%) reported all 3 risk factors.
Prescription
A high proportion of patients were prescribed treatment
for ASCVD secondary prevention as recommended in
the MSF Guidelines (Table 2). Almost all patients were
prescribed statin (98.2%) and antiplatelet (97.3%)
medication. Over three quarters of the patients were
prescribed β-blockers (79.1%) or ACE-I or ARBs.
(75.7%). 83.2% of the patients were prescribed three
recommended drugs: statin, antiplatelet and at least one
anti-hypertensive drug (ACE-I, ARB or β-blockers),
while 73.5% were prescribed all three recommended
drugs among ACE-I/ARB, statin and antiplatelet.
Among patients who were not prescribed all the
recommended drugs, the main reason for not prescrib-
ing ACE-I/ARB or β-blocker, according to prescribing
clinicians, was because there was “no need” for it, in 38.7
and 89.9% of cases respectively. Occurrence of side effects
represented 31.2% of the cases of non-prescription of
ACE-I/ARBs but only 1.1% for β-blockers.
Self-reported adherence
Self-reported adherence rates are presented in Table 3.
Self-reported adherence to individual drugs was in
Table 1 Characteristics of ASCVD patients taking part in cross-sectional survey in MSF clinics, north Lebanon
Characteristics Overall [95% CI]a Abdeh clinic [95% CI] DAZ clinic [95% CI]
Demographic
Age (mean) 60.4 [59.6, 61.3] 60.8 [59.6, 62.1] 60.1 [58.9, 61.3]
Gender (male) 61.9 [57.5, 66.1] 66.0 [59.5, 71.9] 58.3 [52.3, 64.2]
Resident permit 27.2 [23.5, 31.3] 20.2 [15.4, 25.9] 33.3 [27.9, 39.3]
Reads Arabic 58.9 [54.5, 63.2] 56.7 [50.2, 63.1] 60.9 [54.8, 66.6]
ASCVD history
Coronary heart disease 31.5 [27.6, 35.8] 13.0 [9.2, 18.1] 47.5 [41.5, 53.5]
Cerebrovascular disease 26.1 [22.4, 30.1] 27.7 [22.2, 34] 24.6 [19.8, 30.2]
Peripheral vascular disease 1.8 [0.9, 3.4] 1.7 [0.5, 4.5] 1.8 [0.7, 4.4]
Revascularisation 58.8 [54.4, 63] 66.0 [59.5, 71.9] 52.5 [46.5, 58.5]
Risk factors
Diabetes 51.8 [47.3, 56.1] 49.2 [42.7, 55.7] 54.0 [47.9, 59.9]
Smoking 39.7 [35.5, 44.1] 38.2 [32.1, 44.8] 40.9 [35.1, 47.0]
Hypertension 72.2 [68.1, 76.0] 66.4 [60.0, 72.3] 77.2 [71.7, 81.9]
All 3 risk factors 12.1 [9.4, 15.3] 9.2 [6.0, 13.8] 14.5 [10.7, 19.3]
aData are presented as proportions or means with 95% Confidence Intervals
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general high but disparate, with lower rates in DAZ
clinic. Self-reported adherence to antiplatelet treatment
was very high (93.9%), as it was for β-blocker treatment
(90.8%). Self-reported adherence for statins was high in
Abdeh (91.2%) but lower in DAZ (67.7%). The same
trend was observed for ACE-I, with 90.8% of patients in
Abdeh reporting a good level of adherence compared
with 75.2% in DAZ. For patients who were prescribed 3
recommended drugs including one anti-hypertensive
drug, self-reported adherence was 85.2% in Abdeh and
57.3% in DAZ.
Table 4 shows the causes of non-adherence for each
drug that patients reported having taken for four days or
fewer during the previous week, or at a different dose to
the one prescribed (a different number of pills).
Overall (Table 4), the main reason for non-adherence
to one of the drugs was that patients did not understand
the prescription in terms of dose (the number of pills
they had to take each day), and hence did not take
the drug “as prescribed” (46%). This was especially
true for statins (67%) and ACE-Is (47%) but it was
not a reason for non-adherence to antiplatelets. The
second most frequent cause of non-adherence was pa-
tient decision (11%), followed by experiencing side ef-
fects or following doctor’s request (7%). This last
reason was the leading one for low self-reported ad-
herence to antiplatelets (20%).
Non-adherence to statins was associated with having a
first consultation in an MSF clinic more than two years
ago (p = 0.008) and having a history of CHD (p = 0.002),
and revascularisation was associated with increased ad-
herence to statins (p = 0.006). No strong evidence for an
association was found between demographics or other
clinical factors and adherence to any other treatment.
Overall the combined self-reported adherence to pre-
scription of at least three drugs indicated for ASCVD
secondary prevention (statin, antiplatelet and one anti-
hypertensive drug) was low at 43.4% (CI95%: 39.1–47.8)
of the surveyed patients, with a marked difference be-
tween the two clinics: 60.5% (CI95%: 54.0–66.7) in Abdeh
clinic and only 28.6% (CI95%: 23.4–34.4) in DAZ clinic.
Retrospective cohort study
Cardiovascular disease burden
From the opening of each of the two clinics until the
end of April 2017, the total number of ASCVD patients
seen was 1286. Of a total of 16,686 ASCVD consulta-
tions, 92.3% were follow-up consultations (n = 15398).
The consultations for patients with ASCVD represented
24% of the NCD workload (of 69,010 total NCD consul-
tations during this period). Over 50% of the ASCVD
patients had other NCD comorbidities for which they
were also reviewed during their consultations.
Follow-up pattern
Table 5 presents treatment interruption and loss to
follow up patterns while Fig. 1 shows frequency of
follow up and patients' adherence to planned appoint-
ments. In the multivariable logistic regression analysis,
the only variable associated with LTFU was sex; men
had reduced odds of having at least one LTFU episode
(OR = 0.72, 95% CI 0.56 to 0.92, p-value = 0.0099) com-
pared to women.
Discussion
Main findings and comparison with previous studies
Our study shows that a high proportion of clinic work-
load (24%) is related to patients with a diagnosis of
Table 2 Prescribed ASCVD related treatment
Drug Overall [95% CI] Abdeh clinic [95% CI] DAZ clinic [95% CI]
ACE-I or ARB 75.7 [71.7, 79.3] 80.3 [74.64, 85.1] 71.8 [66.0, 77.0]
Statin 98.2 [96.5, 99.1] 95.6 [93.1, 98.4] 99.6 [97.7, 100]
Antiplatelet 97.3 [95.3, 98.4] 95.3 [91.5, 97.5] 98.9 [96.6, 99.7]
Β-blocker (BB) 79.1 [75.2, 82.5] 73.8 [67.6, 79.2] 83.5 [78.5, 87.6]
Statin, antiplatelet, ACE-I/ARB 73.5 [69.4, 77.3] 76.4 [70.3, 81.6] 71.1 [65.2, 76.3]
Statin, antiplatelet, ACE-I/ARB/BB 83.2 [79.6, 86.3] 79.8 [74.0, 84.7] 86.1 [81.3, 89.8]
Table 3 Self-reported adherence among ASCVD patients taking part in cross-sectional study in MSF clinics, north Lebanon
Drug Overall (%, 95CI) Abdeh clinic (%, 95 CI) DAZ clinic (%, 95 CI)
ACE-I 83.8 [79.1, 87.6] 90.8 [85.2, 94.5] 75.2 [67.1, 81.9]
Statin 78.4 [74.4, 81.9] 91.2 [86.5, 94.4] 67.7 [61.7, 73.1]
Antiplatelet 93.9 [91.3, 95.8] 95.6 [91.7, 97.7] 92.5 [88.5, 95.2]
β—blocker 90.8 [87.4, 93.4] 94.1 [75.2, 87.4] 88.3 [83.2, 92.1]
Statin, antiplatelet, ACE-I 69.5 [64.0, 74.6] 82.0 [75.2, 87.4] 54.4 [45.7, 62.8]
Statin, antiplatelet, ACE-I/BB 72.6 [67.2, 77.5] 85.2 [78.7, 90.0] 57.3 [48.5, 65.5]
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ASCVD among those being treated for NCDs in MSF
clinics in northern Lebanon. The mean age (60 years) of
the patients who participated in the cross-sectional sur-
vey is consistent with other studies that found higher
rates of CVD among Syrian refugees in Lebanon older
than 60 years old and with the fact that CVD prevalence
increases with age [25, 27, 30]. A higher proportion of
men among ASCVD patients reflects the increased risk
of ASCVD morbidity and mortality in men globally and
specifically in Syria [31]. This correlates with results
from the Global Health Data Exchange for Syria accord-
ing to which DALYs associated with Ischemic Artery
Diseases and stroke represent 35.5% for men, compared
to 24% of women aged 50–69 years old. This holds true
for this cohort despite the fact that among Syrian refu-
gees in Lebanon there are more adult women than men
in the age ranges 18–59 men and 60+ [22].
In terms of ASCVD history, revascularisation was the
most frequently reported manifestation of CVD, with
more than half (58.8%) of the ASCVD patients having
undergone such a procedure, reflective of the high level
of medical care available in Lebanon and in Syria prior
to the war. However, fewer patients (31.5%) had a
diagnosis of CHD (here defined as angina or MI). The
apparent difference in the prevalence of CHD between
the two clinics (13% in Abdeh and 47.5% in DAZ) may
be due to differences in reporting of medical history. It
appeared that medical teams were not routinely
recording a diagnosis of CHD for patients with previous
revascularisation, and this was more common in Abdeh
clinic, where only 3% of patients with previous revascu-
larisation were documented as having CHD compared to
40% in DAZ clinic.
The high prevalence of risk factors such as hypertension
and diabetes in ASCVD patients is as expected and has
been well documented in similar populations [32–34].
Abdul Rahim et al. reported very similar and increasing
rates of smoking in the Arab world generally [35].
MSF protocols for the secondary prevention of ASCVD
events were generally well followed and treatment pre-
scription was satisfactory, with recommended drugs being
prescribed to at least three quarters of the patients. Ac-
cording to the programme doctors, the main reason for
not prescribing β-blockers or ACE-I/ARB (the two least
prescribed classes of drugs) was that there was “no need”.
It is interesting to note that having the doctors fill the
prescription part of the CRF had a positive side-effect.
For 12.3% of patients they corrected the prescription
immediately by adding recommended drugs that were
found to be missing (either never prescribed or dis-
rupted prescription for no apparent specific reason).
There was clearly room for improvement in prescribing,
but this act of drug review served to increase prescrip-
tion fidelity and shows that the clinicians may benefit
from reminders to review prescriptions from one follow-
up consultation to the next, even when there is a high
workload. Similarly, performing periodic prescribing au-
dits in chronic care programmes may help to combat
prescriber fatigue and inertia.
Overall, patients reported good adherence to their
ASCVD treatment. This finding is consistent with those
from a study of adherence to NCD medication of Syrian
refugees in Lebanon [36], although a systematic review
on adherence to CVD medication in resource-limited
settings reported overall adherence at a much lower rate
of 57.5% [37].
We found strong evidence of an association for non-
adherence to statins with first consultation in MSF clinic
taking place more than two years ago and with a CHD
diagnosis. By contrast, we found strong evidence of an
association between previous revascularisation and in-
creased adherence. Although reasons for these were not
explored, it is plausible that the latter group of patients
had a better understanding of the need for statin use
and thus greater motivation for adherence.
Although prescription and self-reported adherence
were acceptable, the combination of the two resulted in
a low overall use of the recommended drugs (43.4%).
Overall use was much lower in DAZ clinic (28.6%) than
Table 4 Causes of non-adherence (all patients)
Ranking Overall (N = 228) ACE-I (N = 53) Statin (N = 108) Antiplatelet (N =
30)
BB (N = 37)
1st Did not understand
prescription (46%)
Did not understand
prescription (47%)
Did not understand
prescription (67%)
Doctor’s request
(20%)
Did not understand
prescription (22%)
2nd Patient’s decision (11%) Patient’s decision (17%) Side effects (6%) Forgot (16%),
Side-effects, (16%)
Patient’s decision (16%)
3rd Side-effects (7%),
Doctor’s request (7%)
Doctor’s request (6%), other
(6%)
Patient’s decision (5%),
MSF-stock ruptures (5%)
Patient’s decision
(11%)
Side effects (14%)
Table 5 Patterns of loss to follow up or treatment interruption,
follow-up frequency and adherence to planned appointments
Loss to follow up Total (n = 1,286)
No return after 1st visit 138 (10.7%)
One or more treatment interruption 743 (58%)
More than one interruption 157 (12.2%)
Lost to follow up at end of study period 510 (39.7%)
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in Abdeh clinic (60.5%), resulting from a lower self-re-
ported adherence in DAZ clinic.
Analyses of the apparent adherence disparity between the
clinics revealed that the main causes were provider-driven
(due to drug shortages leading to short-term changes in
dosing, which were inadequately explained to patients), and
could therefore be mitigated. On questioning, many patients
appeared to have poorly understood their prescription: they
had taken the drugs for at least five days during the previous
week, but not the appropriate number of pills, anecdotally
showing genuine surprise when this was explained to them.
This was especially true for statins (accounting for 70% of
low adherence cases) as well as for ACE-I. This issue corre-
lated with a change in prescription due to drug shortages
that happened a month prior to the study, which led to ei-
ther a change in the pill strength (simvastatin 20mg to sim-
vastatin 10mg), a change between ACE-I drugs (enalapril to
captopril), or change of class of drug (ARB instead of ACE-
I), in many cases necessitating a change in the daily number
of pills taken. In some cases, complete stock outs occurred
leading to treatment interruptions.
The second most frequent cause for low adherence
was a patient’s decision not to take certain drugs either
for the whole week or on a certain number of days.
These two reasons highlight the importance of patient
support and education in the care process, the value of
patient-centeredness, shared decision making, under-
standing the patient’s beliefs and concerns regarding
medications, and tailoring advice and support to each
patient [38].
Patients partially followed their appointment schedule:
just under half of the consultations took place on the ap-
pointment date and an additional 20.3% occurred within
the following week. However, having more than half of
patients not attend at their scheduled appointment time
has a direct implication for work organisation, teams’
workload and quality of care. Improving (and simplify-
ing) the appointment system - such as with a patient
reminder system - may prove beneficial. Two-monthly
appointments were recommended in the project for
stable patients, with potential benefits of decreased clinic
workload and burden of attendance for patients. The
proportion of patients on this schedule was relatively
low but increasing. It was higher in DAZ (22.7%) than in
Abdeh (6%), likely due to Abdeh clinic having opened
more recently, meaning that patients attending this
clinic had had less time to stabilize.
More than half of the patients had at least one episode
of loss to follow-up. The process for tracking these
patients properly may need to be reinforced, partly to
help with understanding contributory causes and identi-
fying those that are modifiable.
Strength and limitations
To our knowledge this is the first study to evaluate the bur-
den of patients with ASCVD and describe their manage-
ment with a focus on use of recommended medications in
humanitarian settings. Most of the data analysed for this
study were collected during the cross-sectional component,
which lasted one month. Completeness and reliability were
therefore increased compared to routinely collected data.
The participation rate was high at 94.3% and so selection
bias is likely to be minimal.
The data presented here are only representative of
Syrian refugees with known ASCVD seeking care in two
MSF clinics in Northern Lebanon, and it might not be
representative of the overall ASCVD burden among
Syrians living in Lebanon.
The main biases that could affect the results of this
study are recall bias and acquiescence bias that may have
led to an overestimated self-reported adherence. There
is a broad range of validated adherence surveys,
Fig. 1 Distribution of delay between appointment and visit date
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specifying timeframes from 1 day to 12months [39]. We
tried to minimise potential recall bias by asking about
adherence only over the preceding 7 days. This tool has
been used in other studies but is not externally validated
[28]. Adherence questions were asked by the PSEC
nurses, who are part of the regular MSF care team. Until
then, they were little involved in the management of
ASCVD patients. However, half of the participants also
had diabetes and PSEC nurses play an active role in the
care of diabetic patients. The existing and ongoing care
relationship between the PSEC nurses and some patients
could have led to response bias for some of the patients.
Reporting of the number and type of ASCVD events
could also be affected by recall bias, especially since
many patients arrived from Syria without any medical
records. However, validation studies using a variety of
tools over the last decade have shown a relatively robust
sensitivity of 78–98% for self-reported MI [40].
The adherence question was asked for ACE-I but not
for ARB. For the analyses of the overall adherence and
use of drugs, we assumed that the adherence to ARB
would have been the same as the adherence to ACE-I.
For the retrospective study we reported the data in-
cluded in the existing information system and there was
a degree of missing data. However, there were no miss-
ing data in the cross-sectional survey.
Regarding patients lost to follow-up, some may have
been considered lost to follow-up at the time of analysis
but might have returned to care at a later date. This
study has not explored the characteristics of the subpop-
ulation that had unplanned periods of loss to follow up
or definitively left the programme.
Implications for research
This research yielded some results that could be inter-
esting to investigate further. Among the main causes of
non-adherence, we identified the lack of understanding
by patients of the prescription of multiple drugs. The
use of a fixed dose combination drug (a polypill) includ-
ing a statin, aspirin, and at least one anti-hypertensive
has been shown to be effective in research studies and
may be a simple strategy to increase adherence in hu-
manitarian settings [41]. Additionally, exploring patient
perceptions, experiences and understanding of statins
and their medical importance to coronary heart disease
could help us to understand why patients were less likely
to be adherent to statins than to other drugs. Further
studies to explore the reasons for loss to follow up
would be important to better understand the patient and
clinic level barriers in order to develop specific strategies
to tackle these.
Overall, it is important to design and evaluate simplified
models of care to help increase prescription rates, adher-
ence, and overall use of cardiovascular secondary
prevention medications and to ensure regular follow-up of
patients with ASCVD, while balancing with clinic
capacity. Potential components of these simplified models
could include decreased consultation frequency for stable
patients as well as an enhanced community involvement,
especially in the context of protracted humanitarian crises.
Community health programmes have been reported to
positively support vulnerable populations and refugees to
access health care [9, 36]. Because of MSF’s substantial ex-
perience in managing patients with HIV/AIDS (also ne-
cessitating chronic care) in humanitarian settings it could
be interesting to adapt some of the lessons learnt from
these models to patients with ASCVD.
Finally, developing an information system that could bet-
ter monitor the impacts of programmatic changes could be
a powerful tool to support informed decision-making.
Conclusion
The burden of CVD and other NCDs is increasing globally
and even more rapidly in LMICs. This epidemiological
transition has a direct impact on the needs of crisis-affected
populations and hence on the care that needs to be pro-
vided by aid organisations. Providing adequate CVD care in
limited-resource settings remains a challenge. MSF has de-
veloped a model to provide NCD care in high-workload
humanitarian settings, utilising non-specialist general prac-
titioners, with tasks shifted from doctors to nurses, and
using a rationalised list of standardized drugs. Our study
showed overall acceptable results in these two clinics in
Lebanon: patients were following their care recommenda-
tions with reasonable follow-up rates and adherence to
treatment, and prescriptions aligned with the protocols.
However, MSF is working to continue to improve, refine
and evaluate effective and sustainable NCD care models for
humanitarian settings.
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